Gilead Sciences

Anna Cumaraswamy

New Zealand has a well-established and robust clinical research sector that has been growing steadily over the years. The country has a strong research infrastructure, with world-class research institutes, universities, and hospitals that collaborate on clinical research studies. Some of the notable areas of clinical research in New Zealand include cancer, cardiovascular disease, mental health, and infectious diseases.

Mental health research is an important area of focus in New Zealand. Mental health disorders are prevalent in New Zealand, with one in five people experiencing a mental health issue each year. The government and research institutions have recognized the need to address mental health issues through research, policy, and practice.

Some of the key areas of mental health research in New Zealand include:

1. Depression and anxiety: Depression and anxiety are two of the most common mental health issues in New Zealand. Research is focused on understanding the causes of these disorders, developing effective treatments, and improving access to care.

2. Addiction: Addiction is a significant issue in New Zealand, with high rates of alcohol and drug abuse. Research is focused on understanding the causes of addiction, developing effective interventions, and improving access to treatment.

3. Suicide prevention: Suicide rates in New Zealand are high, particularly among young people and Māori communities. Research is focused on developing effective suicide prevention strategies and improving access to mental health services.

4. Māori mental health: There is a growing body of research on the mental health needs of Māori communities in New Zealand. This research is focused on developing culturally appropriate interventions to improve mental health outcomes for Māori.

5. Youth mental health: There is a significant need for research on youth mental health in New Zealand. Many young people in the country experience mental health issues, and research is focused on identifying risk factors, developing interventions, and improving access to services.

Douglas Pharmaceuticals is a New Zealand-based pharmaceutical company that specializes in the development, manufacture, and marketing of specialty generic and repurposed drugs. Douglas has a strong focus on research and development with a keen interest in mental health research, with a team of scientists working on developing new and innovative products. The company has a proven track record and has developed several successful products, including prescription medications for a range of conditions within dermatology, cardiovascular and mental health fields.

Douglas Pharmaceuticals is committed to quality and safety and has a state-of-the[1]art manufacturing facility in Auckland that is fully licensed and certified to international quality standards.

" New Zealand has a well-established and robust clinical research sector that has been growing steadily over the years. The country has a strong research infrastructure, with world-class research institutes, universities, and hospitals that collaborate on clinical research studies "

Douglas has developed R-107, an oral extended-release dose of racemic ketamine as a potential add-on or monotherapy for treatment resistant depression. Douglas has completed their Phase 2 in New Zealand, Australia, Singapore, and Taiwan and announced encouraging results in 2022. Douglas is now gearing up for a Global Phase 3 in order to fully understand the potential benefits and risks of ketamine for depression treatment, to date it has shown significant promise as a potentially life-saving treatment option for people with treatment-resistant depression.

Douglas is aligned to New Zealand’s focus on improving mental health outcomes for all New Zealanders, with a particular focus on addressing the mental health needs of Māori communities and young people. The company also has a strong commitment to sustainability, with initiatives in place to reduce waste, energy consumption, and greenhouse gas emissions